EP1343456A1 - Produits pour soins capillaires a teneur en cristaux liquides presentant des phases cubiques - Google Patents

Produits pour soins capillaires a teneur en cristaux liquides presentant des phases cubiques

Info

Publication number
EP1343456A1
EP1343456A1 EP01994693A EP01994693A EP1343456A1 EP 1343456 A1 EP1343456 A1 EP 1343456A1 EP 01994693 A EP01994693 A EP 01994693A EP 01994693 A EP01994693 A EP 01994693A EP 1343456 A1 EP1343456 A1 EP 1343456A1
Authority
EP
European Patent Office
Prior art keywords
cosmetic
water
group
preparations
hair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01994693A
Other languages
German (de)
English (en)
Inventor
Jörg SCHREIBER
Harald Albrecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP1343456A1 publication Critical patent/EP1343456A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0295—Liquid crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring

Definitions

  • the present invention relates to hair care products which contain disperse liquid crystals and to processes for their preparation.
  • the present invention relates to hair cosmetic preparations for the care of the hair and the scalp.
  • the present invention relates to preparations which serve to strengthen the individual hair and / or to give the hairstyle overall hold, fullness and shine.
  • the entire human body with the exception of the lips, the palms of the hands and the soles of the feet, is hairy, but for the most part with barely visible wool hairs. Because of the many nerve endings at the hair root, hair is sensitive to external influences such as wind or touch and is therefore a part of the sense of touch that should not be underestimated.
  • the most important function of the human head hair today should be to help shape the human appearance in a characteristic way. Similar to the skin, it fulfills a social function, since its appearance makes a significant contribution to interpersonal relationships and the self-esteem of the individual.
  • the hair consists of the hair shaft protruding freely from the skin - the keratinized (dead) part, which actually represents the visible hair - and the hair root stuck in the skin - the living part, in which the visible hair is constantly being newly formed.
  • the hair shaft for its part, is made up of three layers: a central part - the so-called hair mark (medulla), which, however, is regressed in humans and is often completely absent - as well as the marrow (cortex) and the outer cuticle layer (cuticle) up to ten layers thick that covers the whole hair. Unless there are pathological changes, human hair can practically not be improved in its newly grown state.
  • the part of a hair located near the scalp accordingly has an almost closed cuticle layer. However, in particular the cuticle layer as the outer covering of the hair, but also the inner area below the cuticle are exposed to particular stresses caused by environmental influences.
  • the hair can be damaged in its physical, chemical and morphological properties by various external influences.
  • the hair is affected by intense sunlight and other climatic influences such as differences in humidity and temperature, mechanical stress due to intensive combing or brushing, cosmetic hair treatments such as repeated hair coloring and in particular bleaching and hair deformation (e.g. perms), but also by frequent washing with degreasing surfactants, especially in the area of the hair tips, stressed and strained. Oxidative loads in particular often damage the hair.
  • the hair becomes brittle and loses its shine; the surface of the hair is roughened and matting and knotting occur. As a result, the hair is extremely difficult to comb and detangle.
  • Hair care products with a combability-improving and nourishing effect are usually used in the form of conditioners and can achieve a considerable improvement in the condition of the hair. They can be formulated in such a way that they not only serve to care for the individual hair, but also improve the overall appearance of the hairstyle, for example by giving the hair more volume, fixing the hairstyle over a longer period of time or improving its manageability. Hair care products of this type generally represent emulsions or suspensions which contain, inter alia, fatty alcohols, waxes and oils and also quaternary ammonium compounds. Quaternary ammonium compounds are absorbed onto the hair and are often still detectable on the hair after several washes. The shine of the hair depends on its surface condition.
  • lipids are to be understood as fats, ie carboxylic acid esters of glycerol.
  • this term is understood to mean a group of water-insoluble molecules which are distinguished by at least one pronounced hydrophilic molecular region and at least one pronounced lipophilic molecular region.
  • the phosphoric acid esters of acylated glycerols, the so-called “phospholipids” and other compounds belong to this group, which is quite inhomogeneous overall, of chemical compounds.
  • phosphatidylcholines are, for example, the lecithins, which are characterized by the general structure
  • R 'and R typically represent unbranched aliphatic radicals having 15 or 17 carbon atoms and up to 4 cis double bonds.
  • lipids Due to the structural conditions, lipids generally do not form real molecular solutions in vitro, for example in a mixture with water. Rather, they come together, for example, to form so-called micelles, in which the lipophilic molecular areas of the lipid molecules are directed towards the inside of the micelle and the hydrophilic areas of the lipid molecules represent the outer area of the micelles.
  • Lipid membranes can be linear, curved (cubic phases, L3 phases) or self-contained (vesicles, L4 phases), for example.
  • Disperse liquid crystals which are cubic or inverse-cubic phases, are known per se. They can be formally derived from crystallographic spherical packs in which the spheres represent micelles (FIG. 1), which can be regularly arranged in a grid (FIG. 2). In addition to these micellar cubic or inversely micellar cubic structures, there are so-called bicontinuously cubic structures in which lipid double membranes are involved instead of micelles. These can curve into spheres (liposomes, vesicles) or form extensive three-dimensional structures, which have been mathematically described by Black, for example.
  • the imaginary minimal surface is the bilayer membrane curved in space, which, due to the regular structure, allows the formation of two independent water channels.
  • the total curvature of such a structure is zero, no energy is required to form such structures other than that for mixing the components, e.g. Glyceryl monooleate and water. Bicontinuity is created by the three-dimensional water channels and the continuous bilayer membrane.
  • Cubic phases can also occur in three-phase systems consisting of lipid phase, water phase and surfactant phase.
  • H mean a hexagonal phase
  • C a cubic phase
  • L a lamellar phase
  • jH an inverse hexagonal phase
  • the document WO 97/14394 describes cosmetic compositions which contain at least one amphiphilic material which is capable of form water-insoluble liquid crystalline phase with a multidimensional periodicity once this composition is applied to the skin.
  • WO 97/13528 describes pharmaceutical preparations containing active substances and fatty acid esters which can form liquid-crystalline phases, the preparations either already containing liquid-crystalline phases or precursors therefor which form these phases when in contact with moisture.
  • WO 96/27364 describes preparations for water-free dosage forms with acetylated monoglycerides, which are characterized by occlusive films.
  • WO 95/34287 describes preparations for the controlled release of active substances which contain diacylglycerides and phospholipids which form cubic phases with one another.
  • WO 99/56725 also describes preparations for the controlled release of active substances, these preparations being liquid, characterized by a content of phospholipids, pharmaceutically acceptable solvents and fatty acids and forming gel phases in the presence of water.
  • WO 94/24993 and US 5593663 describe antiperspirant preparations which form cubic phases on contact with sweat. These preparations accordingly have sweat-absorbing properties.
  • WO 94/06400 also discloses lipsticks which may contain cubic structures
  • WO 94/04122 describes diacylglycerides for increasing melanin in melanocytes
  • WO 92/20377 describes preparations of glycerylmonolin oleates for transdermal applications.
  • glyceryl monolinoleates for the treatment of winter xerosis is reported in WO 92/10995.
  • ethanol-containing glyceryl monooleate formulations can be used for the purpose of increased penetration of active substances, and cubic phases are also described in WO 84/02076.
  • WO 98/47487 describes pharmaceutical preparations for the controlled release of active substances which are in the form of liquid-crystalline phases and can be used on injured and undamaged skin as well as nails and mucous membranes.
  • US 5756108 and EP 968704 disclose cosmetic, dermatological or pharmaceutical preparations which contain an oil phase dispersed in a water phase, the oil droplets being stabilized by cubic gel particles.
  • Fragmented cubic phases are known per se.
  • EP B 0 643 620 describes the production and pharmacological use of colloidal particles based on cubic phases.
  • dispersed cubic phases based on phytantriol are described in US 5834013 and in EP 686 386.
  • Dispersions of at least two amphiphilic components are also described in EP 968 704. -
  • Dispersed cubic phases are also called "cubosomes”.
  • glyceryl oleate can form dispersed cubic phases in the presence of suitable fragmenters.
  • WO 93/06921 (page 12, line 51 to page 14, line 5) describes that a cubic phase can be converted into a fragmented cubic phase by a) block copolymers, b) polymers (such as alginates, propylene glycol alginates, gum, Arabic, xanthan, carragenan, PVP and carboxymethyl cellulose), c) Ultrasound in the presence of surface-active substances with an HLB value of 15 or greater, or d) Lamellar phase-forming fragmenters. Also disclosed here (page 20, line 24) are a number of suitable amphiphilic polymers and nonionic, anionic, cationic or zwitterionic fragmenters which can be used advantageously.
  • WO 99/15171 describes nicotine-containing preparations which u. a. can be present in the form of cubic liquid crystals or as corresponding dispersions.
  • the object of the present invention was therefore to remedy the disadvantages of the prior art shown.
  • cosmetic or dermatological preparations containing disperse liquid crystals which cubic phases from a) a periodic membrane system, comprising at least one particle former and optionally one or more natural or synthetic lipids, and b) one or more water areas and c) one or more fragmenters, and an additional content of d) one or more skin-compatible additive (s) selected from the components compatible with the components according to a), b) and c) Group which is formed from cosmetic oils, sterols, phospholipids, polyols, antioxidants and active ingredients as a galenical base formulation for cosmetic or dermatological hair care products to remedy the disadvantages of the prior art.
  • a periodic membrane system comprising at least one particle former and optionally one or more natural or synthetic lipids, and b) one or more water areas and c) one or more fragmenters, and an additional content of d) one or more skin-compatible additive (s) selected from the components compatible with the components according to a), b) and c) Group which is formed from cosmetic oils, sterols
  • the preparations according to the invention are extremely satisfactory preparations in every respect, which surprisingly show excellent cosmetic properties and are distinguished by excellent skin tolerance. It has surprisingly been found that the disadvantages of the prior art are avoided by the additions according to d) and the integrity of the cubic particles is nevertheless ensured. In particular, the skin tolerance of the administration system can be significantly improved by the additives according to the invention.
  • the content of skin-compatible additives according to the invention according to d) (one or more compounds) in the preparations is preferably 0.01 to 20% by weight, particularly preferably 0.01 to 10% by weight, based on the total weight of the preparation.
  • cosmetic oil components such as macadamia oil
  • control such as. B. cholesterol or the skin-compatible additives according to the invention
  • phospholipids such as phosphatidylcholine
  • glycerol is the skin-compatible additive according to the invention, it is advantageous to choose its concentrations from the range from 0.5 to 20% by weight, based on the total weight of the formulation.
  • antioxidants are the skin-compatible additives according to the invention, it is advantageous to choose their respective concentrations from the range from 0.01 to 0.5% by weight, based on the total weight of the formulation.
  • Suitable antioxidants are e.g. B. Butylhydroxytoluene, propyl gallate and tocopherols and derivatives (z. B. Vitamin E - acetate), in particular those which are available under the trade name Mixed Tocopherols MTS 70 from the company ADM.
  • Moisturizers are substances or mixtures of substances that give cosmetic or dermatological preparations the property of reducing the release of moisture from the skin layer (also called transepidermal water joss (TEWL)) and / or hydrating the skin layer positively after application or distribution on the skin surface to influence.
  • TEWL transepidermal water joss
  • moisturizers for the purposes of the present invention are, for example, glycerol, lactic acid, pyrrolidone carboxylic acid and urea. Furthermore, it is particularly advantageous to use polymeric moisturizers from the group of water-soluble and / or water-swellable and / or water-gelable polysaccharides. Particularly advantageous are, for example, hyaluronic acid, chitosan and / or a fucose-rich polysaccharide, which is filed in the Chemical Abstracts under the registration number 178463-23-5 and z. B. under the name FucogeHOOO from the company SOLABIA S.A. is available.
  • ceramides in particular ceramide III
  • phosphatidylcholine or combinations of both into the dispersed cubic membrane of the preparations according to the invention.
  • the skin care effects increase with the content of dispersed cubic particles or the content of the unsaturated glyceryl ester in the preparations according to the invention.
  • Particularly advantageous embodiments of the cosmetic and dermatological hair care preparations in the sense of the present invention contain in addition to the features a) to d) mentioned one or more with the components according to a), b), c) and d) compatible thickener.
  • Low viscosity (sprayable) preparations according to the invention which do not contain thickeners preferably have viscosities of less than 2,000 mPas, in particular less than 1,500 mPas;
  • Flowable lotions in the sense of the present invention generally have viscosities of about 2,000 mPa-s up to about 6,000 mPa-s.
  • the viscosity of the formulations according to the invention can advantageously also be significantly greater than 6,000 mPa.s; so z. B.
  • lotion-like / cream-like formulations preferably contain at least one thickener, preferably in a concentration of up to about 10% by weight, based on the total weight of the preparations.
  • the following can advantageously be used:
  • Celluloses and their derivatives polyacrylic acids and their derivatives, acrylic acid copolymers and their derivatives, starches and their derivatives, pectins and their derivatives, alginates and their derivatives, keratins and their derivatives, guar and their derivatives, collagens and their derivatives, hyaluronic acid and their derivatives , Chitosans and their derivatives, carragenans and their derivatives, layered silicates and their derivatives, siloxanes and their derivatives, polyethylene glycols and their derivatives, in particular of the ABA type (A: hydrophobic, B: hydrophilic), polyethylene glycol / polypropylene glycol block copolymers, polyquaternium compounds and their Derivatives, polyvinylpyrrolidones and their derivatives, polyvinylpyrrolidone copolymers and their derivatives.
  • A hydrophobic
  • B hydrophilic
  • Hydroxyethyl cellulose, hydroxypropyl methyl cellulose, cetyl hydroxyethyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, PEG 150 distearate, xanthan gum and carbomers are particularly advantageous for the purposes of the present invention.
  • xanthan (CAS No. 11138-66-2), also called xanthan gum, which is an anionic heteropolysaccharide which is generally formed from corn sugar by fermentation and is isolated as the potassium salt. It is produced by Xanthomonas campestris and some other species under aerobic conditions with a molecular weight of 2 * 106 to 24 * 106. Xanthan is formed from a chain with -1, 4-bound glucose (cellulose) with side chains. The structure of the subgroups (“repeated units”) consists of glucose, mannose, glucuronic acid, acetate and pyruvate.
  • Thickeners which are advantageous according to the invention are also polymers of acrylic acid, in particular those selected from the group of the so-called carbomers or carbopoles (Carbopole is actually a registered trademark of the B.F. Goodrich Company).
  • Carbopols are compounds of the general structural formula
  • the carbopole group also includes acrylate-alkyl acrylate copolymers, for example those which are distinguished by the following structure:
  • R ' represents a long-chain alkyl radical and x and y numbers which symbolize the respective stoichiometric proportion of the respective comonomers. These carbopoles are also advantageous for the purposes of the present invention.
  • Examples of advantageous carbopoles are types 907, 910, 934, 940, 941, 951, 954, 980, 981, 1342, 1382, 2984, 5984 and ETD 2001, these compounds being able to be present individually or in any combination with one another.
  • Carbopol 981, 1382 and 5984 are particularly preferred (both individually and in combination with other hydrocolloids).
  • copolymers of C10-30-alkyl acrylates and one or more monomers of acrylic acid, methacrylic acid or their esters which are comparable to the acrylate-alkyl acrylate copolymers.
  • the INCI name for such compounds is "Acrylates / C 10-30 Alkyl Acrylate Crosspolymer”.
  • Particularly advantageous are those available under the trade names Pemulen TR1 and Pemulen TR2 from B.F. Goodrich Company.
  • the total amount of one or more thickeners in the finished cosmetic or dermatological preparations is particularly advantageously chosen to be less than or equal to 3.0% by weight, very particularly between 0.01 and 1.5% by weight, based on the total weight of the preparations.
  • compositions are also obtained if antioxidants are used as additives or active ingredients.
  • the preparations advantageously contain one or more antioxidants. All of the antioxidants suitable or customary for cosmetic and / or dermatological applications can be used as inexpensive, but nevertheless optional, antioxidants.
  • the antioxidants are advantageously selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-camosine, D-camosine, L- Carnosine and its derivatives (e.g. anserine), carotenoids, carotenes (e.g. ' carotene, carotene, lycopene) and their derivatives, lipoic acid and their derivatives (e.g. dihydroliponic acid), aurothioglu- cose, propylthiouracil and other thiols (e.g.
  • amino acids eg glycine, histidine, tyrosine, tryptophan
  • imidazoles eg urocanic acid
  • peptides such as D, L-camosine, D-camosine, L- Carnos
  • thioredoxin glutathione, cysteine, Cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, linoleyl, cholesteryl and glyceryl esters) and their salts, di -Lauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (eg buthioninsulfoximines, homocysteine suifoximine, buthionine sulfones, pentathione, hexa- sulfoxin, heptathione), hexa-, hexa- imine compatible doses (
  • (metal) chelators e.g. hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic Acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g. linolenic acid, linoleic acid, oleic acid), folic acid and their derivatives, ubiquinone and ubiquinol and their derivatives, vitamin C and derivatives (e.g.
  • ascorbyl palmitate Mg-ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g. vitamin E acetate), vitamin A and derivatives (vitamin A palmitate) as well as konyferyl benzoate of benzoin, rutinic acid and its derivatives, ferulic acid and its derivatives, butylated hydroxytoluene, butylated hydroxytoluene, butyl Nordihydro-guaiaxic acid, nordihydroguajaretic acid, trihydroxy-butyrophenone, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (eg ZnO, ZnSO4) selenium and its derivatives (eg selenium methionine), stilbenes and their derivatives (eg stilbene oxide, trans-stilbene oxide ) and the derivatives suitable according to the invention (salts, esters, ethers, sugars, nucleotides, nucle
  • Water-soluble antioxidants can be used particularly advantageously for the purposes of the present invention.
  • compositions according to the invention are very good vehicles for cosmetic or dermatological active ingredients, preferred active ingredients being antioxidants which can protect the skin / hair from oxidative stress.
  • preferred active ingredients are antioxidants which can protect the skin / hair from oxidative stress.
  • Preferred antioxidants are vitamin E and its derivatives and vitamin A and its derivatives.
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 to 20% by weight, in particular 0.1 to 10% by weight, based on the total weight the preparation.
  • vitamin E and / or its derivatives represent the antioxidant (s)
  • vitamin A or vitamin A derivatives or carotenes or their derivatives represent the antioxidant or antioxidants, it is advantageous to derive their respective concentrations from the Range from 0.001 to 10 wt .-%, based on the total weight of the formulation to choose.
  • the active ingredients can also be selected very advantageously from the group of lipophilic active ingredients, in particular from the following group:
  • vitamins e.g. Ascorbic acid and its derivatives
  • vitamins of the B and D series very cheap vitamin
  • the active substances from the group of refatting substances, for example purcellin oil, Eucerit and Neocerit.
  • the active ingredient (s) are also particularly advantageously selected from the group of NO synthase inhibitors, in particular if the preparations according to the invention are intended for the treatment and prophylaxis of the symptoms of intrinsic and / or extrinsic skin aging and for the treatment and prophylaxis of the harmful effects of ultraviolet radiation on the skin ,
  • the preferred NO synthase inhibitor is nitroarginine.
  • the active ingredient (s) are also advantageously selected from the group comprising catechins and bile esters of catechins and aqueous or organic extracts from plants or parts of plants which contain catechins or bile acid esters of catechins, such as the leaves of Plant family Theaceae, especially the species Camellia sinensis (green tea).
  • Their typical ingredients such as polyphenols or catechins, caffeine, vitamins, sugar, minerals, amino acids, lipids are advantageous.
  • Catechins are a group of compounds which are to be regarded as hydrogenated flavones or anthocyanidins and derivatives of "catechins” (catechol, 3,3 ', 4', 5,7-flavanpentaol, 2- (3,4-dihydroxyphenyl) -chroman -3,5,7-triol)
  • Catatechin ((2R, 3R) -3,3 ', 4', 5,7-flavanpentaol) is also an advantageous active substance in the sense of the present invention.
  • Plant extracts containing catechins in particular extracts of green tea, such as. B. extracts from leaves of the plants of the species Camellia spec, especially the teas Camellia sinenis, C. assamica, C. talien- sis or C. irrawadiensis and crosses of these with, for example, Camellia japonica.
  • Preferred active substances are also polyphenols or catechins from the group (-) - catechin, (+) - catechin, (-) - catechin gallate, (-) - gallocatechin gallate, (+) - epicatechin, (-) - epicatechin, (-) -Epicatechin gallate, (-) - epigallocatechin, (-) - epigallocatechin gallate.
  • Flavon and its derivatives are advantageous active substances in the sense of the present invention. They are characterized by the following basic structure (substitution positions specified):
  • flavones usually occur in glycosidated form.
  • the flavonoids are preferably selected from the group of substances of the generic structural formula
  • the flavonoids can also be advantageously selected from the group of substances of the generic structural formula
  • Z1 to Z6 are independently selected from the group H, OH, alkoxy and hydroxyalkoxy, where the alkoxy or hydroxyalkoxy groups can be branched and unbranched and can have 1 to 18 carbon atoms, and wherein Gly is selected from the group the mono- and oligoglycoside residues.
  • Such structures can preferably be selected from the group of substances of the generic structural formula
  • Gly1, Gly2 and GIy3 independently of one another represent monoglycoside residues or. Gly2 or Gly3 can also individually or together represent saturations by hydrogen atoms.
  • Gly1, Gly2 and Gly3 are preferably selected independently of one another from the group of the hexosyl radicals, in particular the rhamnosyl radicals and glucosyl radicals.
  • hexosyl radicals for example allosyl, altrosyl, galactosyl, gulosyl, idosyl, mannosyl and talosyl, may also be used advantageously.
  • pentosyl residues may also be advantageously selected independently of one another from the group H, OH, methoxy, ethoxy and 2-hydroxyethoxy, and the flavone glycosides have the structure
  • Gly1, Gly2 and Gly3 independently of one another represent monoglycoside residues or.
  • Gly2 or GIy3 can also individually or together represent saturations by hydrogen atoms.
  • Gly1, Gly2 and Gly3 are preferably selected independently of one another from the group of the hexosyl radicals, in particular the rhamnosyl radicals and glucosyl radicals.
  • hexosyl radicals for example allosyl, altrosyl, galactosyl, gulosyl, idosyl, mannosyl and talosyl, may also be used advantageously. It can also be advantageous according to the invention to use pentosyl residues.
  • the flavone glycoside (s) from the group consisting of glucosylrutin, glucosylmyricetin, glucosylisoquercitrin, glucosylisoquercetin and glucosylquercitrin.
  • Glucosylrutin is particularly preferred according to the invention.
  • naringin aurantiin, naringenin 7-rhamnoglucosid
  • hesperidin 3 ', 5,7-trihydroxy-4'-methoxyflavanon-7-rutinoside
  • hesperidoside hesparin-7-O-rutinoside
  • Rutin (3,3 ', 4', 5,7-pentahydroxyflyvon-3-rutinoside, quercetin-3-rutinoside, sophorin, birutan, rutabion, taurutin, phytomelin, melin), troxerutin (3,5-dihydroxy-3 ', 4', 7-tris (2-hydroxyethoxy) flavon-3- (6-O- (6-deoxyL-mannopyranosyl) D-glucopyranoside)), monoxerutin (3,3 ', 4', 5- Tetrahydroxy-7- (2-hydroxyethoxy) flavone-3- (6-O- ( ⁇ -deoxy-L-mannopyranosyl) D-glucopyranoside)), dihydro-robinetin (3,3 ', 4', 5 ', 7 -Penta- hydroxyflavanone), taxifolin (3,3 ', 4', 5,7-pentahydroxyflavanone), eriodictyo
  • the active ingredient (s) from the group of ubiquinones and plastoquinones.
  • Coenzyme Q10 which is characterized by the following structural formula, is particularly advantageous:
  • Creatine and / or creatine derivatives are also preferred active substances for the purposes of the present invention. Creatine is characterized by the following structure:
  • Preferred derivatives are creatine phosphate and creatine sulfate, creatine acetate, creatine ascorbate and the derivatives esterified on the carboxyl group with mono- or polyfunctional alcohols.
  • Another advantageous active ingredient is L-carnitine [3-hydroxy-4- (trimethylammonio) -butter-acid-betaine].
  • acyl-carnitine which is selected from the group of substances of the following general structural formula
  • R is selected from the group of branched and unbranched alkyl radicals having up to 10 carbon atoms
  • R is selected from the group of branched and unbranched alkyl radicals having up to 10 carbon atoms
  • Propionylcamitine and in particular acetylcamitine are preferred.
  • Both entantiomers (D- and L-form) can be used advantageously for the purposes of the present invention. It can also be advantageous to use any mixture of enantiomers, for example a racemate of D and L form.
  • the list of the active substances or combinations of active substances mentioned which can be used in the preparations according to the invention is of course not intended to be limiting.
  • the active ingredients can be used individually or in any combination with one another.
  • the solubility of poorly soluble active ingredients such as, for example, biotin in the preparations according to the invention is significantly increased.
  • the preparations can be both low-viscosity and lotion-like or cream-like.
  • lipophilic active ingredients such as Q-10, tocopherole, lipoic acid, ceramide III, ascorbyl palmitate, sericoside and / or nitroarginine is significantly higher than from dosage forms of the prior art.
  • bioadhesivity of the formulations can e.g. B. can be used to obtain a styling effect. It is believed that after topical application the product water evaporates, causing the dispersed cubic phase to change to a cubic phase (or other colloid chemical phases). This cubic lipid film (or the film of other colloid chemical phases) protects against environmental pollutants. Accordingly, such products could also be used as new barrier creams.
  • cosmetic or dermatological preparations according to the present invention are distinguished by very good skin tolerance.
  • glyceryl monooleate glyceryl inoleate or glyceryilinolenate is used, preferably in a concentration of 0.1 to 7.5% by weight, based on the total weight of the preparations.
  • the disperse liquid crystals according to the invention which are cubic phases, z. B. produced by the following methods:
  • the oil phase comprises the particle former (s), the advantageous fat-soluble fragmenter (s) and possibly other fat-soluble additives.
  • the mixture is stirred until homogeneous, with heating.
  • the water phase comprises water and possibly other water-soluble additives.
  • the warm oil phase is added in portions to the water phase at room temperature with vigorous stirring.
  • the mixture is then homogenized using a dispersing device (such as, for example, an Ultra-Turrax, Becomischer, Warrior mixer) or using other conventional methods of homogenization, for example high-pressure homogenization.
  • a dispersing device such as, for example, an Ultra-Turrax, Becomischer, Warrior mixer
  • other conventional methods of homogenization for example high-pressure homogenization.
  • the oil phase comprises the particle or particles, and optionally other fat-soluble additives.
  • the mixture is stirred until homogeneous, with heating.
  • the water phase comprises water, the advantageously water-soluble fragmenter (s) and optionally other water-soluble additives.
  • the warm oil phase is added in portions to the water phase at room temperature with vigorous stirring. Then it is preferably homogenized with a dispersing device (such as an Ultra-Turrax, Becomischer or Warrior mixer).
  • a dispersing device such as an Ultra-Turrax, Becomischer or Warrior mixer.
  • Other conventional methods of homogenization such as, for example, high-pressure homogenization, are also advantageous in the sense of the present invention.
  • the basic lipid of the cubic phase (also called “particle former” in the context of the disclosure) is preferably selected from the group of unsaturated fatty acid monoglycerides, such as, for example, glyceryl monoleate, glyceryl monolinoleate, fatty acid diglycerides such as, for example, diglyceryl dioleate or diglyceryl dilinoleate, and also mixtures of these the substances described above, such as, for example, mixtures of diglyceryl monooleate with diglyceryl dioleate, mixtures of diglyceryl monooleate with diglyceryldilinoleate, etc.
  • other lipoid substances such as phytantriol, and also mixtures of the substances described above, are suitable particle formers for the purposes of the present invention.
  • the particle formers can be present in amounts of 0.1 to 50% by weight, based on the total weight of the cubic phases.
  • the fragmenters can be present in amounts of 0.01 to 45% by weight, based on the total weight of the cubic phases.
  • the fragmenters are surfactants or emulsifiers, which can be both ionic and nonionic in nature. Accordingly, the terms “surfactants” or “emulsifiers” are frequently used below as synonyms for the term “fragmenter”.
  • the hydrophilic proportions of a surfactant molecule it is mostly polar functional groups, for example COO-, -OSO3, -SO3, while the hydrophobic parts usually represent non-polar hydrocarbon residues.
  • Surfactants are generally classified according to the type and charge of the hydrophilic part of the molecule. There are four groups:
  • amphoteric surfactants amphoteric fragmenters
  • nonionic surfactants nonionic fragmenters
  • Anionic surfactants generally have carboxylate, sulfate or sulfonate groups as functional groups. In an aqueous solution they form negatively charged organic ions in an acidic or neutral environment. Cationic surfactants are characterized almost exclusively by the presence of a quaternary ammonium group. In aqueous solution they form positively charged organic ions in an acidic or neutral environment. Amphoteric surfactants contain both anionic and cationic groups and accordingly behave in aqueous solution like anionic or cationic surfactants depending on the pH. They have a positive charge in a strongly acidic environment and a negative charge in an alkaline environment. In the neutral pH range, however, they are zwitterionic, as the following example should illustrate:
  • Anionic surfactants to be used advantageously are acylamino acids (and their salts), such as
  • acyl peptides for example palmitoyl hydrolyzed milk protein, sodium cocoyl hydrolyzed soy protein and sodium / potassium cocoyl hydrolyzed collagen,
  • sarcosinates for example myristoyl sarcosine, TEA-lauroyl sarcosinate, sodium lauroyl sarcosinate and sodium cocoyl sarcosinate
  • taurates for example sodium lauroyl taurate and sodium methyl cocoyl taurate
  • Carboxylic acids and derivatives such as
  • carboxylic acids for example lauric acid, aluminum stearate, magnesium alkanolate and zinc undecylenate,
  • ester carboxylic acids for example calcium stearoyl lactylate, laureth-6 citrate and sodium PEG-4 lauramide carboxylate
  • ether carboxylic acids for example sodium laureth-13 carboxylate and sodium PEG-6 cocamide carboxylate
  • Phosphoric acid esters and salts such as DEA-oleth-10-phosphate and dilureth-4-phosphate
  • acyl isethionates e.g. B. sodium / ammonium cocoyl isethionate
  • alkyl sulfonates for example • sodium cocosmon glyceride sulfate, sodium C12-14 olefin sulfonate, sodium lauryl sulfate acetate and magnesium PEG-3 cocamide sulfate,
  • Sulfosuccinates for example dioctyl sodium sulfosuccinate, disodium laureth sulfosuccinate, disodium lauryl sulfosuccinate and disodium undecylenamido MEA sulfosuccinate
  • Sulfuric acid esters such as
  • alkyl ether sulfate for example sodium, ammonium, magnesium, MIPATIPA laureth sulfate, sodium myreth sulfate and sodium C12-13 pareth sulfate,
  • Alkyl sulfates for example sodium, ammonium and TEA lauryl sulfate.
  • anionic fragmentation aids such as sodium lauroyl lactylate or sodium cococyl glutamate or sodium cocoamphoacetate can also be used to produce cubosomes according to the invention.
  • Quaternary surfactants contain at least one N atom which is covalently linked to 4 alkyl or aryl groups. Regardless of the pH value, this leads to a positive charge.
  • Alkyl betaine, alkylamidopropyl betaine and alkylamidopropyl hydroxysulfain are advantageous.
  • the cationic surfactants used according to the invention can furthermore preferably be selected from the group of the quaternary ammonium compounds, in particular benzyltrialkylammonium chlorides or bromides, such as, for example, benzyldimethylstearylammonium chloride, furthermore alkyltrialkylammonium salts, for example cetyltrimethylammonium chloride or bromide, alkyldimethylhydroxyammonium chloride-bromide, alkyldimethylhydroxyammonium chloride-bromide, alkyldimethylhydroxyethylammonium bromide or bromides, alkyl amide ethyl trimethyl ammonium ether sulfates, alkyl pyridinium salts, for example lauryl or cetyl pyrimidinium chloride, imidazoline derivatives and compounds with a cationic character such as amine oxides, for example alkyl dimethyl amine oxides or alkylaminoe
  • Amphoteric Surfactants are amphoteric surfactants that can be used advantageously
  • acyl- / dialkylethylenediamine for example sodium acylamphoacetate, disodium acylamphodipropionate, disodium alkylamphodiacetate, sodium acylamphohydroxy-propylsulfonate, disodium acylamphodiacetate and sodium acylamphopropionate
  • N-alkylamino acids for example aminopropylalkylglutamide, alkylaminopropionic acid, sodium alkylimidodipropionate and lauroamphocarboxyglycinate.
  • N-alkyl or N-alkenyl betaines with at least 12 carbon atoms such as.
  • Polyether chains are typical of nonionic surfactants.
  • Nonionic surfactants do not form ions in an aqueous medium.
  • Polyethoxylated or polyethoxylated and polypropoxylated O / W emulsifiers are advantageously used (one or more compounds), preferably selected from the following groups
  • R-COO - (- CH2-CH2-O-) n -H where R is a branched or unbranched alkyl or alkenyl radical with at least 12 carbon atoms and n is a number of at least 20, • the etherified fatty acid ethoxylates of the general formula
  • R-COO - (- CH2-CH2-O-) n -R ' where R and R' independently of one another are branched or unbranched alkyl or alkenyl radicals having at least 12 carbon atoms and n is a number of at least 20,
  • esterified fatty acid ethoxylates of the general formula R-COO - (- CH2-CH2-O-) n -C (O) -R ⁇ where R and R 'independently of one another are branched or unbranched alkyl or alkenyl radicals having at least 12 carbon atoms and n represents a number of at least 20,
  • R and R 'independently of one another are branched or unbranched alkyl or alkenyl radicals having at least 12 carbon atoms and n represents a number of at least 20,
  • the polyoxyethylene sorbitol fatty acid ester based on branched or unbranched alkanoic or alkenoic acids with at least 12 carbon atoms and a degree of ethoxylation of at least 20, for example of the sorbeth type, • the alkyl ether sulfates or the acids of these sulfates of the general formula RO - (- CH2-CH2-O-) n-S03-H, where R is a branched or unbranched alkyl or alkenyl radical having at least 12 carbon atoms and n is a number of at least 20.
  • alkyl ether carboxylic acids of the general formula RO - (- CH2-CH (CH3) O-) n-CH2-COOH or their cosmetically or pharmaceutically acceptable salts, where R is a branched or unbranched alkyl or alkenyl radical with at least 10 carbon atoms and n represents a number of at least 2,
  • alkyl ether sulfates or the acids on which these sulfates are based of the general formula RO - (- CH2-CH (CH3) -O-) n-SO3-H with cosmetically or pharmaceutically acceptable cations, where R is a branched or unbranched alkyl or Alkenyl radical having at least 5 carbon atoms and n being a number of at least 2,
  • R-COO-Xn-Ym-R ' where R and R' independently of one another are branched or unbranched alkyl or alkenyl radicals having at least 12 carbon atoms, Y is an oxyethylene group and X is an oxypropylene group and n and m are integers independently of one another from 5 to 100, • the fatty acid ethoxylates / propoxylates of the general formula
  • R-COO-Xn-Ym-H where R is a branched or unbranched alkyl or alkenyl radical having at least 12 carbon atoms, Y is an oxyethylene group and X is an oxypropylene group and n and m are independently integers from 5 to 50. • the polyglycerol ester of the general formula
  • R-COO (CH2CH (OH) CH2OH) x where R corresponds to a branched or unbranched alkyl or alkenyl radical having at least 12 carbon atoms and x a number of at least 10 glycerol units.
  • polysiloxane-polyether copolymers eg DC 193 from Dow Corning
  • polyethoxylated or polyethoxylated and polypropoxylated O / W emulsifier are selected from the groups • of the fatty alcohol ethoxylates of the general formula RO - (- CH2-CH2-O-) nH, where R is one branched or unbranched alkyl or alkenyl radical with at least 12 carbon atoms
  • Atoms and n represent a number of at least 12,
  • esterified fatty acid ethoxylates of the general formula R-COO - (- CH2-CH2-O-) n -C (O) -R ', where R and R' independently of one another are branched or unbranched alkyl or alkenyl radicals with at least 12 C. -Atoms and n represent a number of at least 20,
  • the cholesterol ethoxylates with HLB values from 14 to 19, very particularly advantageously with HLB values from 15 to 17,
  • RO - (- CH2-CH2-O-) n-CH2-COOH or their cosmetically or pharmaceutically acceptable salts where R is a branched or unbranched alkyl or alkenyl radical having at least 12 atoms and n is a number of at least 15, • the Polyoxyethylene sorbitol fatty acid esters based on branched or unbranched alkanoic or alkenoic acids and having a degree of ethoxylation of at least 20, for example of the sorbeth type,
  • the polyethoxylated or polyethoxylated and polyprop ' oxylated O / W emulsifiers selected are particularly advantageously selected from the group of substances with HLB values from 14 to 19, very particularly advantageously with HLB values from 15 to 17, provided that the O / W emulsifiers have saturated radicals R and R '. If the O / W emulsifiers have unsaturated radicals R and / or R ', or if isoalkyl derivatives are present, the preferred HLB value of such emulsifiers can also be lower or higher.
  • One or more oil components can be selected as part of the membrane system of the disperse cubic phase, although this is not absolutely necessary for all systems. Oil components can generally advantageously take up to 3% by weight of the total weight of the cubic phase.
  • the subsequent oil components are equally suitable for forming the oil phase of an overall formulation or for participating in it.
  • the oil constituents are advantageously chosen from the group of the esters from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 carbon atoms.
  • ester oils can then advantageously be selected from the group of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl ethylhexylate ethyl 2-ethylhexyl palylate 2-octyldodecyl palmitate, oleyl oleate, olerlerucate, erucyl oleate, erucylerucate as well as synthetic, semi-synthetic and natural mixtures of such esters, e.g. B. Jojoba oil.
  • the oil components can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, silicone oils, dialkyl ethers, dialkyl carbonates, and the group of saturated or unsaturated, mixed branched or unbranched alcohols, and also the fatty acid triglycerides, especially the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 to 18, carbon atoms.
  • the fatty acid triglycerides can for example be advantageously selected from the group of synthetic, semi-synthetic and natural oils, e.g. B. olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil, macadamia oil, avocado oil, evening primrose seed oil, canola oil, castor oil and the like.
  • the oil components are advantageously selected from the group consisting of 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C12-15-alkyl benzoate, caprylic / capric acid triglyceride, dicacapryl carbonate, dicaprylyl ether.
  • hydrocarbons paraffin oil, squalane and squalene can be used advantageously for the purposes of the present invention.
  • sterols such as cholesterol, lecithins, hydrogenated lecithins and various mixtures of these components.
  • the oil constituents can advantageously also contain cyclic or linear silicone oils or consist entirely of such oils.
  • Cyclomethicone (octamethylcyclotetrasiloxane) is advantageously used as the silicone oil to be used according to the invention.
  • other silicone oils can also be used advantageously for the purposes of the present invention, for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane).
  • the preparations according to the invention can also contain film-forming polymers.
  • film-forming agent polymers with at least partially quaternized nitrogen group pen (hereinafter referred to as "film-forming agent"), those which are selected from the group of substances which carry the name "Polyquatemium” according to the INCI nomenclature (international nomenclature cosmetic ingredient) are preferred, for example:
  • Polyquaternium-2 Chemical Abstracts No. 63451-27-4 e.g. B. Mirapol® A-15 polyquaternium-5 copolymer of acrylamide and methacryloxyethyl-trimethylammonium methosulfate, CAS no. 26006-22-4
  • Polyquaternium-17 CAS-No. 90624-75-2 e.g. B. Mirapol® AD-1 polyquaternium-19 quaternized water-soluble polyvinyl alcohol polyquaternium-20 water-dispersible quaternized polyvinyl octadecyl ether polyquaternium-21 polysiloxane polydimethyldimethylammonium acetate copolymer, e.g. B. Abil® B 9905
  • Polyquaternium-24 Polymeric quaternary ammonium salt of hydroxyethyl cellulose, reaction product with an epoxide substituted with lauryldimethylammonium, CAS no. 107987-23-5, e.g. B. Quatrisoft® LM-200
  • Polyquaternium-28 vinyl pyrrolidone / methacrylamidopropyltrimethylammonium chloride copolymer e.g. B. Gafquat® HS-100
  • Polyquaternium-29 e.g. B. Lexquat® CH Polyquatemium-31 CAS no. 136505-02-7, e.g. B. Hypan® QT 100 Polyquaternium-32 N, N, N-trimethyl-2 - [(2-methyl-1-oxo-2-propenyl) oxy] -ethane ammonium chloride, polymer with 2-propenamide, CAS no. 35429-19-7 Polyquaternium-37 CAS-No. 26161-33-1
  • the cosmetic and dermatological formulations according to the invention can contain auxiliaries of the type normally used in such preparations, for example.
  • auxiliaries of the type normally used in such preparations, for example.
  • Fats, waxes and other natural and synthetic fat bodies preferably esters of fatty acids with alcohols of low C number, eg. B. with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids.
  • the cosmetic or dermatological preparation is a solution or dispersion in the sense of the present invention, the following can be used as solvents:
  • Alcohols, diols or polyols of low C number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or - monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analog products.
  • Water can also be a component of alcoholic solvents.
  • the formulations according to the invention can be in the form of aerosols, that is to say from aerosol containers, squeeze bottles or preparations sprayable by a pump device, or in the form of liquid compositions which can be applied by means of roller devices and in the form of formulations which can be applied from normal bottles and containers, e.g. B. as creams or lotions.
  • they can advantageously be in the form of tinctures, intimate cleansers, shampoos, shower or bath preparations, powders or powder sprays.
  • Suitable blowing agents for cosmetic and / or dermatological preparations which can be sprayed from aerosol containers for the purposes of the present invention are the customarily known volatile, liquefied blowing agents, for example hydrocarbons (propane, butane, isobutane), which can be used alone or as a mixture with one another. Compressed air can also be used advantageously.
  • volatile, liquefied blowing agents for example hydrocarbons (propane, butane, isobutane)
  • Compressed air can also be used advantageously.
  • Active ingredients can advantageously be incorporated, for example, in such a way that oil-soluble or oil-dispersible active ingredients are added to the oil constituents of the dispersed cubic phase and / or that water-soluble or water-dispersible active ingredients are added to the water phase of the dispersed cubic phase. However, it may also be advantageous to add such active ingredients to the medium surrounding the dispersed phase. If the preparation according to the invention is, for example, a preparation which contains a cubic phase dispersed in the water or oil phase, the water and / or the oil phase of the preparation can contain an active ingredient either as the sole active ingredient or as an additional active ingredient to the active substances in the cubic phase.
  • the concentration of the active substances per se can be chosen as desired, but as a rule does not exceed approximately 80% by weight, based on the total weight of the dispersed cubic phase or approximately 40% by weight of the total weight of the cosmetic or dermatological preparation.
  • Glyceryl Oleate 1.9500 Sodium Cocoyl Glutamate 0.0500 Xanthan Gum 0.7500 Glycerin 23.2600 Antioxidant 0.0100 Trisodium EDTA 0.5000 Fragrance (Perfume) 0.1000 Propylparaben 0.1000 Methylparaben 0.2500 Water (Aqua) 73.0300
  • the oil phase comprises the particle or particles, and other fat-soluble additives.
  • the mixture is stirred until homogeneous, with heating.
  • the water phase comprises water, the water-soluble fragmenter and all other water-soluble additives.
  • the warm oil phase is added in portions to the water phase at room temperature with vigorous stirring. Then homogenize with an Ultra-Turrax stirrer, a Beco or a Krieger mixer.
  • the oil phase comprises the particle or particles, and other fat-soluble additives, and the fragmenter.
  • the mixture is stirred until homogeneous, with heating.
  • the water phase comprises water and all other water-soluble additives.
  • the warm oil phase is added in portions to the water phase at room temperature with vigorous stirring. Then homogenize with an Ultra-Turrax stirrer, a Beco or a Krieger mixer.
  • the oil phase comprises the particle or particles, and other fat-soluble additives.
  • the mixture is stirred until homogeneous, with heating.
  • the water phase comprises water, the water-soluble fragmenter and all other water-soluble additives.
  • the warm oil phase is added in portions to the water phase at room temperature with vigorous stirring. Then homogenize with an Ultra-Turrax stirrer, a Beco or a Krieger mixer.
  • the oil phase comprises the particle or particles, and other fat-soluble additives.
  • the mixture is stirred until homogeneous, with heating.
  • the water phase comprises water, the water-soluble fragmenter and all other water-soluble additives.
  • the warm oil phase is added in portions to the water phase at room temperature with vigorous stirring. Then homogenize with an Ultra-Turrax stirrer, a Beco or a Krieger mixer.
  • the oil phase comprises the particle or particles, and other fat-soluble additives.
  • the mixture is stirred until homogeneous, with heating.
  • the water phase comprises water, the water-soluble fragmenter and all other water-soluble additives.
  • the warm oil phase is added in portions to the water phase at room temperature with vigorous stirring. Then homogenize with an Ultra-Turrax stirrer, a Beco or a Krieger mixer.
  • the oil phase comprises the particle or particles, and other fat-soluble additives.
  • the mixture is stirred until homogeneous, with heating.
  • the water phase comprises water, the water-soluble fragmenter and all other water-soluble additives.
  • the warm oil phase is added in portions to the water phase at room temperature with vigorous stirring. Then homogenize with an Ultra-Turrax stirrer, a Beco or a Krieger mixer.
  • the oil phase comprises the particle or particles, and other fat-soluble additives, and the fragmenter.
  • the mixture is stirred until homogeneous, with heating.
  • the water phase comprises water and all other water-soluble additives.
  • the warm oil phase is added in portions to the water phase at room temperature with vigorous stirring. Then homogenize with an Ultra-Turrax stirrer, a Beco or a Krieger mixer.
  • Water (Aqua) 96.2100 The oil phase comprises the particle or particles, and other fat-soluble additives. The mixture is stirred until homogeneous, with heating.
  • the water phase comprises water, the water-soluble fragmenter and all other water-soluble additives.
  • the warm oil phase is added in portions to the water phase at room temperature with vigorous stirring. Then homogenize with an Ultra-Turrax stirrer, a Beco or a Krieger mixer.
  • the oil phase comprises the particle or particles, and other fat-soluble additives, and the fragmenter.
  • the mixture is stirred until homogeneous, with heating.
  • the water phase comprises water and all other water-soluble additives.
  • the warm oil phase is added in portions to the water phase at room temperature with vigorous stirring. Then homogenize with an Ultra-Turrax stirrer, a Beco or a Krieger mixer.
  • the oil phase comprises the particle or particles, and other fat-soluble additives, and the fragmenter.
  • the mixture is stirred until homogeneous, with heating.
  • the water phase comprises water and all other water-soluble additives.
  • the warm oil phase is added in portions to the water phase at room temperature with vigorous stirring. Then homogenize with an Ultra-Turrax stirrer, a Beco or a Krieger mixer.
  • the oil phase comprises the particle or particles, and other fat-soluble additives.
  • the mixture is stirred until homogeneous, with heating.
  • the water phase comprises water, the water-soluble fragmenter and other water-soluble additives.
  • the warm oil phase is added in portions to the water phase at room temperature with vigorous stirring. Then homogenize with an Ultra-Turrax stirrer, a Beco or a Krieger mixer. The dispersion obtained is incorporated into the thickener phase used in parallel.
  • the oil phase comprises the particle or particles, and other fat-soluble additives, and the fragmenter.
  • the mixture is stirred until homogeneous, with heating.
  • the water phase comprises water and all other water-soluble additives.
  • the warm oil phase is added in portions to the water phase at room temperature with vigorous stirring. Then homogenize with an Ultra-Turrax stirrer, a Beco or a Krieger mixer.
  • the oil phase comprises the particle or particles, and other fat-soluble additives.
  • the mixture is stirred until homogeneous, with heating,
  • the water phase comprises water, the water-soluble fragmenter and other water-soluble additives.
  • the warm oil phase is added in portions to the water phase at room temperature with vigorous stirring. Then homogenize with an Ultra-Turrax stirrer, a Beco or a Krieger mixer.
  • the oil phase comprises the particle or particles, and other fat-soluble additives.
  • the mixture is stirred until homogeneous, with heating.
  • the water phase comprises water, the water-soluble fragmenter and other water-soluble additives.
  • the warm oil phase is added in portions to the water phase at room temperature with vigorous stirring. Then homogenize with an Ultra-Turrax stirrer, a Beco or a Krieger mixer.
  • the oil phase comprises the particle or particles, and other fat-soluble additives, and the fragmenter.
  • the mixture is stirred until homogeneous, with heating.
  • the water phase comprises water and all other water-soluble additives.
  • the warm oil phase is added in portions to the water phase at room temperature with vigorous stirring. Then homogenize with an Ultra-Turrax stirrer, a Beco or a Krieger mixer.

Abstract

L'invention concerne l'utilisation de préparations cosmétiques ou dermatologiques à teneur en cristaux liquides dispersés à phases cubiques présentant a) un système de membrane périodique comprenant au moins un générateur de particules et, éventuellement, un ou plusieurs lipides naturels ou synthétiques, et b) une ou plusieurs régions formées par de l'eau, et c) une ou plusieurs fragmentations, ainsi qu'une teneur supplémentaire en d) un ou plusieurs produits d'addition à tolérance cutanée et compatibles avec les composants a), b) et c), sélectionnés dans le groupe formé par les huiles cosmétiques, les stérols, phospholipides, polyols, antioxydants et principes actifs, et e) un ou plusieurs épaississants compatibles avec les composants a), b), c) et d), comme formulation de base galénique pour produits pour soins capillaires cosmétiques ou dermatologiques.
EP01994693A 2000-11-22 2001-11-21 Produits pour soins capillaires a teneur en cristaux liquides presentant des phases cubiques Withdrawn EP1343456A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10057769 2000-11-22
DE2000157769 DE10057769A1 (de) 2000-11-22 2000-11-22 Haarpflegeprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen
PCT/EP2001/013513 WO2002041850A1 (fr) 2000-11-22 2001-11-21 Produits pour soins capillaires a teneur en cristaux liquides presentant des phases cubiques

Publications (1)

Publication Number Publication Date
EP1343456A1 true EP1343456A1 (fr) 2003-09-17

Family

ID=7664134

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01994693A Withdrawn EP1343456A1 (fr) 2000-11-22 2001-11-21 Produits pour soins capillaires a teneur en cristaux liquides presentant des phases cubiques

Country Status (3)

Country Link
EP (1) EP1343456A1 (fr)
DE (1) DE10057769A1 (fr)
WO (1) WO2002041850A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9138429B2 (en) 2011-06-23 2015-09-22 The Procter & Gamble Company Process of forming crystals for use in a personal care composition

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10147545A1 (de) * 2001-09-26 2003-04-10 Beiersdorf Ag Gegen Bakterien Mycota und Viren wirksame Wirkstoffkombinationen auf der Basis von mehrwertigen Alkoholen und dialkylsubstituierten Essigsäuren
WO2007060174A1 (fr) * 2005-11-23 2007-05-31 Nestec S.A. Emulsion huile dans eau utilisee pour creer de nouvelles consistances de produits
EP2488018B1 (fr) * 2009-10-16 2019-05-22 Copperhead Chemical Company Procédés et compositions pour de nouveaux systèmes de distribution de cristaux liquides
US8853269B2 (en) 2010-02-04 2014-10-07 Copperhead Chemical Company Inc. Composition and method for treating infections and promoting intestinal health
JP5248577B2 (ja) * 2010-11-16 2013-07-31 株式会社ナノエッグ 毛髪用組成物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1439244A (en) * 1972-09-29 1976-06-16 Procter & Gamble Liquid crystalline compositions
JPS52114604A (en) * 1976-03-22 1977-09-26 Kao Corp Shampoo composition
SE8206744D0 (sv) * 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
CA2082561A1 (fr) 1991-11-12 1993-05-13 Francis J. Leng Materiaux et compositions antitranspiration
US6325995B1 (en) 1992-09-21 2001-12-04 The Procter & Gamble Company Lipsticks compositions containing association structures
WO1994024993A1 (fr) 1993-04-30 1994-11-10 Unilever Plc Compositions antisudorales
DE4320119A1 (de) * 1993-06-18 1994-12-22 Henkel Kgaa Flüssigkristalline wäßrige Tensidzubereitung
FR2720937B1 (fr) * 1994-06-08 1997-03-28 Oreal Composition cosmétique ou dermatologique sous forme de dispersion, aqueuse et stable, de particules de gel cubique à base de phytantriol et contenant un agent tensioactif à chaîne grasse en tant qu'agent dispersant et stabilisant.
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
FR2726762B1 (fr) * 1994-11-10 1997-01-17 Oreal Composition cosmetique ou dermatologique sous forme d'une dispersion d'une phase huileuse dans une phase aqueuse stabilisee a l'aide de particules de gel cubique et son procede d'obtention
CA2214687A1 (fr) 1995-03-06 1996-09-12 Eastman Chemical Company Vecteur anhydre d'apport d'ingredients cosmetiques
WO1997013528A1 (fr) 1995-10-12 1997-04-17 Gs Development Ab Composition pharmaceutique pour l'administration d'un principe actif sur ou au travers d'une surface cutanee ou muqueuse
GB9521125D0 (en) * 1995-10-16 1995-12-20 Unilever Plc Cosmetic composition
US5776443A (en) * 1996-03-18 1998-07-07 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Hair care compositions
DE19640092A1 (de) * 1996-09-28 1998-04-16 Beiersdorf Ag Strukturen mit Lipid-Doppelmembranen, in deren lipophilen Bereich längerkettige Moleküle eintauchen oder durch hydrophobe Wechselwirkungen an solche Moleküle angedockt sind
DE19713368A1 (de) * 1997-03-29 1998-10-01 Beiersdorf Ag Zubereitungen mit oxidationsempfindlichen Wirkstoffen
SE9703458D0 (sv) * 1997-09-25 1997-09-25 Pharmacia & Upjohn Ab Nicotine compositions and methods of formulation thereof
DE19805703C2 (de) * 1998-02-06 2001-05-03 Cognis Deutschland Gmbh Haarnachbehandlungsmittel
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
FR2780644B1 (fr) * 1998-07-03 2001-07-20 Oreal Composition cosmetique ou dermatologique sous forme d'une dispersion d'une phase huileuse et d'une phase aqueuse, stabilisee a l'aide de particules de gel cubique
JP4570705B2 (ja) * 1999-03-04 2010-10-27 株式会社資生堂 メーキャップ除去用化粧料
DE19919089A1 (de) * 1999-04-27 2000-11-23 Cognis Deutschland Gmbh Haarfärbepräparate
EP1108417B1 (fr) * 1999-12-16 2006-07-05 DSM IP Assets B.V. Composition de teinture pour les cheveux
FR2809957B1 (fr) * 2000-06-08 2002-10-04 Oreal Utilisation de particules de gel cubique comme agent anti-pollution, notamment dans une composition cosmetique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0241850A1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9138429B2 (en) 2011-06-23 2015-09-22 The Procter & Gamble Company Process of forming crystals for use in a personal care composition
US10117813B2 (en) 2011-06-23 2018-11-06 The Procter And Gamble Company Process of forming crystals for use in a personal care composition

Also Published As

Publication number Publication date
DE10057769A1 (de) 2002-05-23
WO2002041850A1 (fr) 2002-05-30

Similar Documents

Publication Publication Date Title
DE10161885B4 (de) Reinigungsprodukte auf Basis ölhaltiger, Mikroemulsionen
EP0934053B1 (fr) Microemulsions cosmetiques ou dermatologiques
DE10213957A1 (de) Vernetzte kosmetische oder pharmazeutische phospholipidhaltige Gele und Emulsionen auf der Basis von ethylenoxidhaltigen oder propylenoxidhaltigen Emulgatoren
EP1470813B1 (fr) Emulsion de nettoyage à taux de matière grasse élevés
KR101934788B1 (ko) 미생물 유래 당지질계 유화제를 이용한 수중유형 화장료 조성물 및 이의 제조방법
EP2029089B1 (fr) Émulsion h/e pour le soin de la main
US20130224133A1 (en) Surfactant-free oil-in-water type emulsion, process for preparation thereof and its uses
KR20160117111A (ko) 식물 유래 계면활성제를 포함하는 화장료 조성물
KR102334446B1 (ko) 투명 세정용 화장료 조성물
DE102005063063A1 (de) Kosmetische Zusammensetzungen zur Hautmattierung
WO2004024110A1 (fr) Preparation cosmetique a base de microemulsions huileuses
EP1704897B1 (fr) Compositions cosmétiques moussables
DE102009029110A1 (de) Antimikrobielle Formulierung
EP1813252A1 (fr) Composition cosmétique pour la matage du cuir chevelu
JP3614511B2 (ja) 日焼け止め用水中油型乳化化粧料
EP1129698A1 (fr) Composition contenant du chitosane et de l'ethanol
EP1343456A1 (fr) Produits pour soins capillaires a teneur en cristaux liquides presentant des phases cubiques
DE10057767A1 (de) Deodorant- und Antitranspirantprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen
DE10057770A1 (de) Hautpflegeprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen ,
EP3075375B1 (fr) Préparation externe pour la peau
DE102020125874A1 (de) Zusammensetzung zur Behandlung von Haaren und der Haut
DE10057768A1 (de) Reinigungsprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen
DE10213956A1 (de) Kosmetische oder pharmazeutische Emulsionen auf der Basis von vernetzten Öltröpfchen
JP3586519B2 (ja) 抗菌性低刺激化粧料
DE102014222569A1 (de) Duschlotionen II

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030623

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060307